CStone Pharmaceuticals...announced that the Phase 3 GEMSTONE-303 study met its primary endpoint of overall survival (OS). Sugemalimab in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvement in OS, compared with placebo plus chemotherapy, as a first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with PD-L1 expression ≥5%. The safety profile was consistent with previous reports of sugemalimab studies, and no new safety signals were identified.